1. Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2
- Author
-
Paulin Nndong Essone, Marielle Leboueny, Selidji T Agnandji, Eliode Cyrien Bongho, Rotimi Myrabelle Avome Houechenou, Amandine Mveang Nzoghe, Ofilia Mvoundza Ndjindji, Anicet Christel Maloupazoa Siawaya, and Joel Fleury Djoba Siawaya
- Subjects
lcsh:Immunologic diseases. Allergy ,0301 basic medicine ,Adult ,Male ,viruses ,Immunology ,Cross Reactions ,Antibodies, Viral ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Immunity ,Seroepidemiologic Studies ,Pandemic ,Medicine ,Humans ,Immunology and Allergy ,Clinical significance ,skin and connective tissue diseases ,Original Research ,biology ,business.industry ,SARS-CoV-2 ,fungi ,virus diseases ,COVID-19 ,Middle Aged ,Immunity, Humoral ,Clinical trial ,body regions ,030104 developmental biology ,Host-Pathogen Interactions ,biology.protein ,Female ,Antibody ,lcsh:RC581-607 ,business ,Immunologic Memory ,030215 immunology - Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the world. Building knowledge around Covid‐19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim We aimed to investigate pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2. Method We have tested the reactivity against SARS‐CoV‐2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS‐CoV‐2 N‐antigen using a well‐validated serological platform; Elecsys assay. Results Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS‐CoV‐2 N‐antigen, suggesting the presence of anti‐SARS‐CoV‐2 N‐antigen antibodies. Conclusion Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical., This is the first report clearly showing a cross‐reactive humoral response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Our data is adding to the accumulating data that point toward the existence of cross‐reactive immunity to SARS‐CoV‐2, as it showed that years before the coronavirus disease 2019 pandemic people had cross‐reactive antibodies against SARS‐CoV‐2.
- Published
- 2020
- Full Text
- View/download PDF